Bluejay Diagnostics, Inc.

BJDX

NASDAQ

Healthcare

Medical - Devices

Acton, MA, US7 employeesbluejaydx.com

$1.95

+0.06(3.17%)

Mkt Cap $884.4K

$1.77

$30.00

52-Week Range

At a Glance

AI-generated

Bluejay Diagnostics, Inc.

8-K

Bluejay Diagnostics issued a corporate update on March 6, 2026, reporting financial results for the year ended December 31, 2025, including $5.2 million in cash and cash equivalents, $6.0 million in stockholders’ equity, and net losses of $6.8 million. The company highlighted progress on its Symphony platform, SYMON II clinical study, manufacturing readiness, and plans to raise at least $20 million in additional capital through 2027.

$884.4K

Market Cap

—

Revenue

-$7M

Net Income

Employees7

Fundamentals

How The Business Makes Money

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Industry Medical - Devices

Activity

What Changed Recently

Financial Results

Mar 5, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,

Securities Modification

Jan 29, 2026

Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defi

Regulation FD

Mar 15, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,

Regulation FD

Mar 11, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,

Regulation FD

Feb 19, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,

Peer Companies

Company	Price	Change	Market Cap	P/E
WGSGeneDx Holdings Corp.	$66.00	+0.73%	$1.9B	-92.3
MLECMoolec Science S.A.	$7.00	+11.46%	$5M	-4.4
UPCUniverse Pharmaceuticals ...	$2.80	+2.56%	$2M	-0.4
TIVCTivic Health Systems, Inc...	$0.95	-5.45%	$1M	-0.2
VTAKCatheter Precision, Inc.	$0.90	-4.06%	$974.4K	—
WINTWindtree Therapeutics, In...	$0.01	+9.33%	$505.6K	—
BCTXZBriaCell Therapeutics Cor...	$0.11	-21.43%	$207.2K	-0.3
ELABPMGC Holdings Inc.	$5.50	-60.72%	$97.2K	-0.0

Analyst View

Company Profile

CIK0001704287

ISINUS0956336087

CUSIP095633608

Phone844 327 7078

Address360 Massachusetts Avenue, Acton, MA, 01720, US

SEC EDGAR